| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H16N2S.ClH |
| Molecular Weight | 256.795 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1=CC=CC(C)=C1NC2=NCCCS2
InChI
InChIKey=QYEFBJRXKKSABU-UHFFFAOYSA-N
InChI=1S/C12H16N2S.ClH/c1-9-5-3-6-10(2)11(9)14-12-13-7-4-8-15-12;/h3,5-6H,4,7-8H2,1-2H3,(H,13,14);1H
Xylazine was developed as an antihypertensive agent. During clinical studies in people xylazine was found to have excessive central nervous system depressant effects and it was subsequently introduced for veterinary use as a sedative, analgesic and relaxant. Xylazine is a potent alpha-2 adrenergic agonist. Xylazine in horses and Cervidae may occasionally cause slight muscle tremors, bradycardia with partial A-V heart block and a reduced respiratory rate. Movement in response to sharp auditory stimuli may be observed.
CNS Activity
Originator
Approval Year
Doses
AEs
PubMed
Patents
Sample Use Guides
Horse Dosage:
Intravenously–0.5 mL/100 lbs body weight (0.5 mg/lb)
Intramuscularly–1.0 mL/100 lbs body weight (1.0 mg/lb)
Route of Administration:
Other
GLP-compliant studies on mutagenicity included Salmonella-microsomal assay with and without metabolic activation (0.4 to 12 mg of Xylazine on plate, with and without metabolic activation), mammalian forward point mutation assay (HPRT locus) in Chinese hamster lung cells (V79) (2 to 40 ug of Xylazine per ml, with metabolic activation and 62 to 1250 ug of Xylazine per ml, without metabolic activation). The compound to be devoid of mutagenic potential.
ACTIVE MOIETY
SUBSTANCE RECORD
